Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ)
Lanzhou, CN
LanZhou Foci Pharmaceutical Co.,Ltd. is a prominent pharmaceutical entity based in China, primarily focused on the manufacturing and distribution of traditional Chinese medicines. Its diverse product line, offered under the "Min Shan" and "Foci" brand names, encompasses a variety of formats, including pills, tablets, capsules, and granules. Beyond its production activities, the company actively pursues research and development initiatives aimed at pioneering novel herbal remedies. Its global footprint extends to approximately 27 countries, with key export markets including the United States, Canada, Japan, Australia, Russia, Ukraine, Singapore, Indonesia, Thailand, Malaysia, New Zealand, and Hong Kong. Established in 1929, the firm's headquarters are located in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. operates as a subsidiary of the Lanzhou Foci Pharmaceutical Factory.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.04% | +2.77% | -5.35% | -14.03% | -12.49% | -9.95% | -7.27% | -41.19% | -5.12% | -24.47% | +122.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-6.6% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-19.8% Q1'26: +16.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+10.5% Q1'26: +25.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.2% Q1'26: +10.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.5% Q1'26: +5.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.24× ★ Q1'26: 0.84× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
544.58M
est: 777.95M (-30.0%)
|
628.82M
est: 1.04B (-39.6%)
|
| EBITDA |
122.89M
est: 110.84M (+10.9%)
|
137.68M
est: 148.28M (-7.1%)
|
| EBIT |
88.69M
est: 66.05M (+34.3%)
|
84.58M
est: 88.35M (-4.3%)
|
| Net Income |
74.28M
|
74.85M
|
| SGA |
98.96M
est: 91.34M (+8.3%)
|
146.91M
est: 122.20M (+20.2%)
|
| EPS |
0.15
|
0.15
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guo Lin Chai | Deputy General Manager | — | male |
| Jinfeng Yue | Chief Financial Officer | — | female |
| Junhui Wang | Secretary of the Board | — | male |
| Ling Wang | Accounting Supervisor | — | — |
| Shuangxi Qian | Executive Vice President & Director | — | male |
| Xiao Yun Feng | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002644.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
